Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluciclitite + bevacizumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination drug consisting of fluciclitite and bevacizumab. Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis and thereby restricting tumor blood supply and growth[6][8][10]. It is widely used in oncology, approved for several cancers including colorectal, lung, ovarian, renal cell carcinoma, glioblastoma, cervical cancer, and hepatocellular carcinoma when combined with various chemotherapies[3][6][8]. Fluciclitite does not appear in major drug databases or scientific literature as an established pharmaceutical agent or active ingredient; it may be a misspelling or an unrecognized/experimental compound. Therefore, the mechanism of action for this component cannot be determined from available sources.
- Other names
- fluciclitite + bevacizumab
02
Targets
Beyond the preview
Go deeper on fluciclitite + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluciclitite + bevacizumab.